All News

4 August 2007

Bayer HealthCare and Regeneron initiate Phase 3 global development program for VEGF Trap-Eye in wet age-related macular degeneration (AMD)Antibodies

3 August 2007

Macrogenics Begins Global Phase 2/3 Protege Study In Recent-onset Type 1 Diabetes MellitusAntibodies

3 August 2007

Genmab regains rights to HuMax-TACAntibodies

2 August 2007

Phase 2a Multi-dose Study Initiated By Medimmune In Patients With Asthma To Further Expand Anti-interleukin-9 ProgramAntibodies

2 August 2007

ImmunoGen, Inc. Initiates Phase II Clinical Trial of HuC242-DM4Antibodies

1 August 2007

Joint FDA Advisory Committee Recommends Approval of TYSABRI(R) for the Treatment of Moderate to Severe Crohn’s DiseaseAntibodies

1 August 2007

YM BioSciences initiates patient enrolment in phase II colorectal cancer trial with EGFR antibodyAntibodies

1 August 2007

Preliminary Data Add New Mechanistic Insights to Activity of Anthrax Anti-Toxin, Valortim(TM)Antibodies

1 August 2007

ImmunoGen, Inc. Earns Milestone with Start of Trastuzumab-DM1 Phase II TestingAntibodies

31 July 2007

BioWa Introduces its Second Technology to Dramatically Enhance Antibody Effector Function and the Launch of AccretaMab(TM) PlatformAntibodies

28 July 2007

US Food & Drug Administration approves Privigen(TM)Antibodies

26 July 2007

Progenics Presents Additional Positive Clinical Results for HIV-Entry Inhibitor PRO 140 at International AIDS MeetingAntibodies

26 July 2007

Actemra monotherapy demonstrates significant clinical benefit in patients with rheumatoid arthritisAntibodies

24 July 2007

MedImmune Announces Interim Phase 1 Study Results for Potential Asthma TherapyAntibodies

24 July 2007

Amorfix acheives first milestone in herapeutic ALS partnership with Biogen IdecAntibodies

21 July 2007

Avastin receives positive opinion in Europe for first-line treatment of patients with advanced lung cancerAntibodies

20 July 2007

Medarex Announces Advancement of Antibody Development by PartnerAntibodies

20 July 2007

Glenmark purchases rights to two therapeutic antibodies from ChromosAntibodies

19 July 2007

Medarex Announces Initiation by Licensing Partner of Phase III Clinical Trial for Muckle Wells SyndromeAntibodies

18 July 2007

Secondary endpoints of phase II/III study confirm clear benefits from treatment with removab(R) for patients with malignant ascitesAntibodies

17 July 2007

XOMA Initiates Phase I U.S. Trial in Type 2 Diabetes for XOMA 052, Monoclonal Antibody With Therapeutic Potential in Multiple Inflammatory DiseasesAntibodies

14 July 2007

CSL Behring Completes Enrollment for Phase III Registration Trial of Next Generation of Subcutaneous ImmunoglobulinAntibodies

13 July 2007

Phase II Study of IMC-A12 for Advanced Colorectal Cancer Has Commenced Patient EnrollmentAntibodies

13 July 2007

Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung CancerAntibodies

13 July 2007

Amgen and Daiichi Sankyo announce agreement for denosumab in JapanAntibodies

12 July 2007

Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Lung Cancer PatientsAntibodies

12 July 2007

TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer TreatmentAntibodies

11 July 2007

Peregrine Pharmaceuticals Initiates Bavituximab Clinical Trial in HCV Patients Co-Infected With HIVAntibodies

11 July 2007

Actemra: latest phase III study shows significant improvement in symptoms of patients with rheumatoid arthritisAntibodies

10 July 2007

MacroGenics IND for West Nile Virus Monoclonal Antibody is ActiveAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CD40 Agonists & CD40/L Antagonists Pipeline Review

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

TSLP Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

c-Met-Targeted Antibody Therapy Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Report Package: “Drug the Undruggable” Technologies